PharmEasy may acquire new businesses

PharmEasy would use the proceeds from this IPO to prepay or repay its outstanding debt of ₹1,929 crore, the DRHP highlighted. The company will be looking to invest ₹1,259 crore to fund organic growth initiatives.

It has also set aside another ₹1,500 crore would be spent on inorganic growth initiatives through acquisition and organic growth initiatives.

PharmEasy has already made three big acquisitions this year to grow its business. This includes rival Medlife, publicly listed diagnostics chain Thyrocare and Aknamed, which is a cloud-based hospital supply chain management startup.